Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Comparison of 15% versus 5% sucrose intakes as part of a eucaloric diet in overweight/obese subjects: impact on insulin resistance, insulin secretion, postprandial glucose levels and vascular compliance
Source of recordUK Trials
ISRCTNISRCTN50808730
Date ISRCTN assigned21/02/2008
Local reference number(s)RGHT000460
Public titleComparison of 15% versus 5% sucrose intakes as part of a eucaloric diet in overweight/obese subjects: impact on insulin resistance, insulin secretion, postprandial glucose levels and vascular compliance
Scientific title
AcronymN/A
Disease/condition/study domainOverweight/obesity and risk of type 2 diabetes mellitus
Study hypothesis15% sucrose intake is detrimental to insulin action when compared to 5% sucrose intake as part of a eucaloric diet in overweight/obese individuals.
Design/methodologyRandomised cross-over trial
Research ethics reviewEthics approval received from the Regional Ethics Committee for Northern Ireland on the 30th October 2007 (ref: HSC REC 3 - REC number 07/NIR03/93).
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Healthy male and female volunteers
2. Overweight/obese (Body Mass Index [BMI] 25 - 35 kg/m^2)
3. Over 18 years old
Participants - exclusion criteria1. A history of cardiac, hepatic or renal disease
2. Due to the use of radioisotopes, women of child bearing age will be excluded unless they are taking effective contraceptive precautions
Patient information material
Anticipated start date01/11/2007
Anticipated end date01/08/2009
Status of trialOngoing
Target number of participants12 - 15
InterventionsEach subject will undergo two dietary intervention periods, each six weeks long separated by a four week washout period. Both diets are matched for macronutrient profile and differ in their micronutrient profile, in that one will have 5% sucrose and the other 15% sucrose content.
Primary outcome measure(s)Insulin resistance, assessed at the end of each six week dietary period using the euglycaemic hyperinsulinaemic glucose clamp technique.
Secondary outcome measure(s)1. Glucose tolerance tests, performed at the beginning and end of each six week dietary period to assess postprandial glucose levels and insulin secretion
2. Plasma lipids
3. Vascular compliance; pulse wave analysis will be done at the beginning and end of each dietary period to assess vascular compliance
4. Glycaemic control
5. Blood pressure
Sources of funding1. The Sugar Bureau (UK)
2. Northern Ireland Research and Development Office (UK)
Sponsor nameBelfast Health and Social Care Trust (UK)
Sponsor details(at the Royal Hospitals site)
Royal Victoria Hospital
Grosvenor Road
Belfast
United Kingdom
BT12 6BA
Sponsor websitehttp://www.belfasttrust.hscni.net/
Contact nameDr Steven Hunter
Contact detailsThe Regional Centre for Endocrinology and Diabetes
Royal Victoria Hospital
Grosvenor Road
Belfast
United Kingdom
BT12 6BA
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN50808730
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central